Positive top-line results from the pivotal BLUE-C study showed that the next-generation Cologuard met all study endpoints and improved every top-line metric, including a 30% lower false positive rate compared to DeeP-C, the FDA registrational trial for Cologuard.
Results from an international clinical trial, published June 15 in The Lancet, show that the selective targeted therapy, fruquintinib resulted in a statistically significant improvement in overall survival and progression-free survival.
Led by Stanford University School of Medicine’s Department of Urology, researchers found that Avenda Health’s machine learning model, Unfold AI, and novel cancer probability metric was shown to be accurate and effective in identifying the extent of the cancer, not just location.
A genetic marker discovered by UT Southwestern Medical Center researchers could help physicians predict which patients with hepatocellular carcinoma are most likely to develop resistance to the drug lenvatinib.
Updated efficacy and safety results from a phase II single-arm trial (SGN35-027) evaluating the antibody-drug conjugate Adcetris (brentuximab vedotin) in combination with the PD-1 inhibitor nivolumab and standard chemotherapy agents doxorubicin and dacarbazine for the frontline treatment of patients with early-stage classical Hodgkin lymphoma showed a 98% overall response rate and a 93% complete response rate at the end of treatment.
Researchers at the Icahn School of Medicine at Mount Sinai have discovered a trio of immune cells within tumor niches that are associated with immunotherapy response in hepatocellular carcinoma.
People experiencing racial discrimination are more reluctant to get vaccinations, according to a study conducted by researchers at the University of Arkansas for Medical Sciences Office of Community Health & Research.
Mitochondria that power cellular activity fragment and change shape in breast cancer cells that migrate to the brain, an adaptation that appears necessary for the cells to survive, UT Southwestern Medical Center researchers report in a study. The findings, published in Nature Cancer, could lead to novel ways to prevent brain metastases.
The American Society of Clinical Oncology has issued new clinical guidance for best treating patients with gastrointestinal cancer amidst a nationwide shortage of carboplatin and cisplatin.
Adjuvant treatment with mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with Keytruda (pembrolizumab) demonstrated a statistically significant and clinically meaningful improvement in distant metastasis-free survival (DMFS) for patients with resected high-risk melanoma (stage III/IV) in a phase IIb study.
